{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:36:12Z","timestamp":1793644572660,"version":"4.5.1"},"reference-count":39,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100004564","name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","doi-asserted-by":"crossref","award":["451-03-68\/2022-14\/200043"],"award-info":[{"award-number":["451-03-68\/2022-14\/200043"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite efficacy of anti-PD-1 blockade in treatment of metastatic melanoma (MM), many patients achieve rapid disease progression (DP). Therefore, the aim of this study is to better define biomarkers for DP by analysing levels of circulating cytokines TGF-\u03b2, IFN-\u03b3, IL-6, IL-8 and IL-10 in MM patients prior to anti-PD-1 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cytokine levels were evaluated before therapy with pembrolizumab in peripheral blood of BRAF wild-type (wt) MM patients by ELISA method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we give pretherapy levels for circulating TGF-\u03b2, IFN-\u03b3, IL-6, IL-8 and IL-10 in BRAFwt MM patients and analyse them according to metastasis stage (M1a+M1\u2009b, M1c, M1d groups), lactate dehydrogenase (LDH) level and occurrence of DP. Increased IL-6 level was found in M1d group (central nervous system metastasis), while LDH+patients (LDH \u2265460\u2009IU\/L) have increased IL-6 and IL-8 values that correlate with LDH level. Also, IL-6 correlates with C reactive protein values. Furthermore, patients with DP have significantly higher IL-6 level compared with non-DP patients. Conversely, the other analysed cytokines are similar in investigated groups of MM patients. By receiver operating characteristics curve analysis, pretherapy IL-6 level was found to be a biomarker for the occurrence of DP with cut-off value of 3.02\u2009pg\/mL. Patients in M1d stage are prevalent in the group with IL-6 \u22653.02\u2009pg\/mL that is characterised with reduced progression-free survival and higher pretherapy IL-8 and LDH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evidence in this study implies that baseline IL-6 could be a biomarker of DP and poor prognosis in BRAFwt MM patients treated with pembrolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2022-208615","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T13:21:18Z","timestamp":1675862478000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy"],"prefix":"10.1136","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-5437","authenticated-orcid":false,"given":"Katarina","family":"Mirja\u010di\u0107 Martinovi\u0107","sequence":"first","affiliation":[{"name":"Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vuleti\u0107","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Ti\u0161ma Mileti\u0107","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Matkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161ica","family":"Gavrilovi\u0107","sequence":"additional","affiliation":[{"name":"Data Centre, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ninkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-128X","authenticated-orcid":false,"given":"Vladimir","family":"Juri\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Babovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2025120521443703000_77.5.343.1","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"2025120521443703000_77.5.343.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"2025120521443703000_77.5.343.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2025120521443703000_77.5.343.4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025120521443703000_77.5.343.5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14737140.2020.1724539","article-title":"Predictive biomarkers of response to immune checkpoint inhibitors in melanoma","volume":"20","author":"Nebhan","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025120521443703000_77.5.343.6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fonc.2018.00270","article-title":"Biomarkers for immune checkpoint inhibitors in melanoma","volume":"8","author":"Kitano","year":"2018","journal-title":"Front Oncol"},{"issue":"Pt 2","key":"2025120521443703000_77.5.343.7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2017.09.004","article-title":"Emerging biomarkers for cancer immunotherapy in melanoma","volume":"52","author":"Axelrod","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"2025120521443703000_77.5.343.8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00351","article-title":"Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer","volume":"5","author":"Bridge","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2025120521443703000_77.5.343.9","doi-asserted-by":"crossref","first-page":"670391","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2025120521443703000_77.5.343.10","doi-asserted-by":"crossref","unstructured":"Galdiero MR , Marone G , Mantovani A . Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 2018;10. doi:10.1101\/cshperspect.a028662","DOI":"10.1101\/cshperspect.a028662"},{"key":"2025120521443703000_77.5.343.11","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0019"},{"key":"2025120521443703000_77.5.343.12","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2025120521443703000_77.5.343.13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjd.16892","article-title":"The new 8th edition of TNM staging and its implications for skin cancer: a review by the British association of dermatologists and the Royal College of pathologists, U.K","volume":"179","author":"Keohane","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025120521443703000_77.5.343.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025120521443703000_77.5.343.15","doi-asserted-by":"crossref","first-page":"19002","DOI":"10.1038\/s41598-020-75812-0","article-title":"Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients","volume":"10","author":"Stanojkovi\u0107","year":"2020","journal-title":"Sci Rep"},{"key":"2025120521443703000_77.5.343.16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2025120521443703000_77.5.343.17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-Term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025120521443703000_77.5.343.18","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"2025120521443703000_77.5.343.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2019.01.001"},{"key":"2025120521443703000_77.5.343.20","doi-asserted-by":"crossref","unstructured":"Gong Y , Liang S , Zeng L , et al . Effects of blood sample handling procedures on measurable interleukin 6 in plasma and serum. J Clin Lab Anal 2019;33. doi:10.1002\/jcla.22924","DOI":"10.1002\/jcla.22924"},{"key":"2025120521443703000_77.5.343.21","doi-asserted-by":"crossref","first-page":"260643","DOI":"10.1155\/2012\/260643","article-title":"A synopsis of serum biomarkers in cutaneous melanoma patients","volume":"2012","author":"Vereecken","year":"2012","journal-title":"Dermatol Res Pract"},{"key":"2025120521443703000_77.5.343.22","doi-asserted-by":"crossref","first-page":"104235","DOI":"10.1016\/j.ebiom.2022.104235","article-title":"Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma","volume":"83","author":"Rossi","year":"2022","journal-title":"EBioMedicine"},{"key":"2025120521443703000_77.5.343.23","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4030022","article-title":"The IL-8\/IL-8R axis: a double agent in tumor immune resistance","volume":"4","author":"David","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"2025120521443703000_77.5.343.24","doi-asserted-by":"publisher","DOI":"10.3109\/07853890009011772"},{"key":"2025120521443703000_77.5.343.25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12916-022-02506-x","article-title":"C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and mendelian randomization analysis","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"key":"2025120521443703000_77.5.343.26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bjc.6602043","article-title":"Diagnosing melanoma patients entering American joint Committee on cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase","volume":"91","author":"Deichmann","year":"2004","journal-title":"Br J Cancer"},{"key":"2025120521443703000_77.5.343.27","doi-asserted-by":"crossref","unstructured":"Laino AS , Woods D , Vassallo M , et al . Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 2020;8. doi:10.1136\/jitc-2020-000842","DOI":"10.1136\/jitc-2020-000842"},{"key":"2025120521443703000_77.5.343.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0118"},{"key":"2025120521443703000_77.5.343.29","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200506000-00009"},{"key":"2025120521443703000_77.5.343.30","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1255-3"},{"key":"2025120521443703000_77.5.343.31","doi-asserted-by":"crossref","unstructured":"Keegan A , Ricciuti B , Garden P , et al . Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 2020;8. doi:10.1136\/jitc-2020-000678","DOI":"10.1136\/jitc-2020-000678"},{"key":"2025120521443703000_77.5.343.32","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1038\/s41598-021-90397-y","article-title":"Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study","volume":"11","author":"Kauffmann-Guerrero","year":"2021","journal-title":"Sci Rep"},{"key":"2025120521443703000_77.5.343.33","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13226"},{"key":"2025120521443703000_77.5.343.34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jid.2021.12.012","article-title":"Evaluation of plasma IL-6 in patients with melanoma as a prognostic and checkpoint immunotherapy predictive biomarker","volume":"142","author":"Wang","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025120521443703000_77.5.343.35","doi-asserted-by":"crossref","unstructured":"Hardy-Werbin M , Rocha P , Arpi O , et al . Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology 2019;8. doi:10.1080\/2162402X.2019.1593810","DOI":"10.1080\/2162402X.2019.1593810"},{"key":"2025120521443703000_77.5.343.36","doi-asserted-by":"crossref","unstructured":"Lippitz BE , Harris RA . Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology 2016;5. doi:10.1080\/2162402X.2015.1093722","DOI":"10.1080\/2162402X.2015.1093722"},{"key":"2025120521443703000_77.5.343.37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/107327480901600307","article-title":"Diagnosis and treatment of melanoma brain metastasis: a literature review","volume":"16","author":"Sloan","year":"2009","journal-title":"Cancer Control"},{"key":"2025120521443703000_77.5.343.38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010142","article-title":"The network of cytokines in brain metastases","volume":"13","author":"Fares","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025120521443703000_77.5.343.39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41392-022-00872-9","article-title":"Targeting polarized phenotype of microglia via IL6\/JAK2\/STAT3 signaling to reduce NSCLC brain metastasis","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2022-208615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:44:49Z","timestamp":1764999889000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2022-208615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/jcp-2022-208615"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2022-208615","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}